Team Members Profile
Team Members Profile
George Hampton

Chief Executive Officer

Chief Executive Officer Mr. Hampton joined Currax Pharmaceuticals in April of 2019 as Chief Executive Officer and serves on its board of directors. Prior to joining Currax, Mr. Hampton served as executive vice president, primary care business unit for Horizon Pharmaceuticals (HZNP), a public biopharmaceutical company. In this role he was tasked with leading the forward-looking strategy, as well as establishing operational goals for the business. Previously, Mr. Hampton served as executive vice president, global orphan business unit and international operations for Horizon Pharmaceuticals. He has more than 25 years of experience as a successful executive in the pharmaceutical and biotech field on both a national and international scale including specific expertise in rare disease (ACTIMMUNE, RAVICTI, PROCYSBI), autoimmune (HUMIRA), primary care, orthopedic (CELEBREX), diabetes (BYETTA), anti-infectives and cardiovascular spaces. This includes roles of increasing responsibility in sales, marketing and operations at G.D. Searle, Abbott, (now AbbVie), Amylin and Horizon Pharmaceuticals. Hampton earned his Bachelor of Science from Miami University in Oxford, Ohio. He serves on the board of Amyrt Pharmaceuticals (AMYT.L), a biopharmaceutical company. Additionally, he serves on the board of IMAC (NASDAQ: IMAC) regeneration medical centers.

Terry Evans

Chief Operating Officer

Chief Operating Officer Terry joined Currax in 2019 as Chief Operating Officer. His expertise is in launching new companies focused on commercial operations and all aspects of Trade relations. He has over 20 years of pharmaceutical experience. Prior to Currax he was senior vice president and general manager of managed care and global trade & distribution at Horizon Pharma where he led teams responsible for the launch or relaunch of 9 medicines, global 3PL’s, government and commercial payer pricing and contracting, order to cash, specialty pharmacy networks, trade and operations. In 2015 he also led, as general manager, the primary care business unit responsible for DUEXIS, VIMOVO and PENNSAID 2% where his team integrated new medicines, expanded both the sales force and direct to patient distribution model. Prior to Horizon, Terry spent 13 years in the dermatology specialty pharmaceutical space with Graceway Pharma and Medicis Pharmaceuticals taking on roles of increasing responsibility through sales, training, marketing, managed care, trade, operations and general management. Terry is also a subject matter expert in direct to patient distribution, HUB services, pharmacy networks as well as the founder of UniteRx, a specialty physician dispensing company. Terry has a Bachelor of Arts in Management and Human Relations from Trevecca Nazarene University in Nashville, TN.

Michelle Parsons

Chief Financial Officer

Chief Financial Officer Michelle joined Currax Pharmaceuticals in August of 2019 as Chief Financial Officer. Prior to joining Currax, Michelle served as senior vice president, financial planning & analysis for Horizon Therapuetics (HZNP), a public biopharmaceutical company. Michelle has over 20 years of experience leading corporate finance, financial reporting, business planning, and systems implementation in the pharmaceutical/medical device industry at the US and global level, including 4 years at Horizon Pharma, 7 years at Fenwal/Fresenius Kabi, and 10 years at Dade Behring.

Aaron Baratta

Vice President, Sales

Vice President, Sales Aaron joined Currax in June of 2019 as Vice President of Sales. His expertise is in launching new companies focused on sales and culture development. He has over 20 years of pharmaceutical experience in various sales leadership positions. Prior to Currax he was Group Vice President of Sales at Horizon Pharma reporting to the GM’s for 3 separate business units focused on sales strategies, talent acquisition, incentive comp design and people leadership development. As the Vice President of Sales at Horizon for the primary care business, sales for DUEXIS, VIMOVO and PENNSAID 2% grew from < 80M to 600M in 3 years.

Prior to Horizon, Aaron helped build 3 start-up pharmaceutical companies with Victory Pharma, Cornerstone Bio Pharma and Biovail all in sales leadership roles launching new salesforces.

Aaron has a Bachelor of Arts in Marketing with a concentration in Sales and Sales Management at Arizona State University in Tempe, Arizona.

Laura Lustig

Vice President, Human Resources

Laura Lustig joined Currax Pharmaceuticals in January of 2020 as the Vice President, Human Resources. Prior to joining Currax, Laura served as the vice president, human resources for Cardiac Science Corporation, a private equity-medical device firm. Previously, Laura was appointed the vice president, human resources for Horizon Therapeutics (HZNP), a public biopharmaceutical company. Laura has more than 25 years of experience leading global human resources building high-performance teams and winning or strong cultures, talent development, organizational change strategies aligned with growth and transformations. Laura spent nine of those years in HR leadership roles at Baxter International, and Fenwal, Inc.

Erika Tooman, Esq.

Senior Vice President, General Counsel

Senior Vice President, General Counsel Erika Tooman is Senior Vice President, General Counsel of the Company. She has broad transactional, business development, corporate governance, litigation, intellectual property, and regulatory experience. Her successful track record in strategic intellectual property counseling and portfolio growth and management has been a key contributor to the success of many licensing and M&A deals. Prior to joining Currax, Ms. Tooman served as Vice President, Associate General Counsel at Pernix Therapeutics, where she oversaw the Contracts, Regulatory and Quality departments, managed intellectual property and litigation, and provided general corporate legal support. Previously, Ms. Tooman was Senior Counsel and a Leadership Team member for Ikaria, Inc. where she grew the world-wide intellectual property portfolio and supported a corporate change of control, R&D spin-off and S-1 filing, culminating with a corporate acquisition by Mallinckrodt Pharmaceuticals in 2015. Ms. Tooman earned her J.D. from Brooklyn Law School, M.A degree from Columbia University, and B.A from Franklin & Marshall College.